Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone acetate
Drug ID BADD_D01434
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D00979
MeSH ID D000077555
PubChem ID 5877
TTD Drug ID Not Available
NDC Product Code 0009-0026; 10695-041; 38779-0144; 46439-8767; 82298-117; 0009-0274; 50090-6024; 60219-1574; 0009-0306; 68788-8082; 76420-262; 0781-3516; 51552-0958; 0009-3073; 76420-260; 25021-821; 0009-0280; 50090-0436; 49452-4688; 71052-161; 25021-820; 70121-1552; 76420-081; 60722-1007; 0009-3475; 55150-313; 63187-474; 70121-1573; 70121-1574; 52128-148; 42023-239; 42023-240; 55150-314; 51927-0000; 63275-9942; 65089-0016; 50090-0556; 51662-1429; 22552-0023; 50090-5894; 60219-1573
UNII 43502P7F0P
Synonyms Methylprednisolone Acetate | Methylprednisolone-21-acetate | Methylprednisolone 21 acetate | Acetyl-Methylprednisolone | Acetyl Methylprednisolone | Depo-Medrone | Depo Medrone | Depo-Medrol | Depo Medrol | Methylprednisolone Acetate, (11beta,16beta)-isomer | Methylprednisolone Acetate, (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C24H32O6
CAS Registry Number 53-36-1
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased insulin requirement05.06.01.006; 14.06.01.006---
Infection11.01.08.002---
Infection susceptibility increased10.02.01.046; 11.01.08.004---
Injection site abscess08.02.03.021; 11.01.08.023; 12.07.03.021---
Injection site infection08.02.03.019; 11.01.08.005; 12.07.03.008---
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia17.15.03.002; 19.02.01.002--
Intestinal perforation07.04.06.002---
Intracranial pressure increased17.07.02.002---
Intraocular pressure increased13.07.04.002---
Irritability08.01.03.011; 19.04.02.013--
Large intestine perforation07.04.06.005; 12.02.03.005--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001---
Malaise08.01.01.003--
Mania19.16.02.002--
Meningitis11.01.03.001; 17.06.03.001--
Menstruation irregular05.05.01.008; 21.01.01.005--
Metabolic acidosis14.01.01.003---
Monoplegia17.01.04.003---
Mood swings19.04.03.001---
Muscle atrophy15.05.03.003; 17.05.03.004---
Muscle disorder15.05.03.014---
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial rupture02.04.02.002; 12.01.11.002---
Myopathy15.05.05.001---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages